Claims
- 1. A therapeutic agent comprising a covalent covalent complex according to the formula HARFM-Th, where HARFM is a high axial ratio forming microstructure material selected from the group consisting of tubules, cochleate cylinders, helical ribbons, twisted ribbons, and mixtures thereof the Th being a therapeutic covalently attached to molecules assembled into the high axial ratio microstructure.
- 2. The therapeutic agent according to claim 1 where the Th is attached to the HARM by a spacer.
- 3. The therapeutic agent according to claim 2 wherein the spacer is a polypeptide.
- 4. The therapeutic agent according to claim 3 wherein the polypeptide comprises an enzyme recognition site whereby enzymes can cleave the spacer at the recognition site.
- 5. The therapeutic agent according to claim 1 wherein the release of therapeutic by the agent follows 0-order kinetics.
- 6. A method for delivering the covalent complex of claim 1 to an animal or person, comprising administering an effective amount of the covalent complex self-assembled into a high axial ratio microstructure .
- 7. The therapeutic agent according to claim 1 wherein the therapeutic is a lipid.
- 8. The therapeutic agent according to claim 1 wherein the high axial ratio forming microstructure material is itself a therapeutic.
- 9. The therapeutic agent according to claim 1 wherein the therapeutic is selected from the group consisting of nucleic acids, conventional pharmaceuticals and mixtures thereof.
- 10. A therapeutic agent according to claim 9 wherein the nucleic acid is DNA.
CROSS REFERENCE TO RELATED APPLICATION
This application claims priority from copending U.S. provisional patent application, No. 60/025,137, filed on Nov. 22, 1995, which is incorporated herein by reference.
US Referenced Citations (3)
Non-Patent Literature Citations (1)
Entry |
Tovchilin in BBRC. 85, #3, pp. 983-990, Dec. 1978. |